31,673 XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Terry Coelho | Director, EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 69,875 | 69,875 (0%) | 0% | 0 | Common Stock | |
| Malte Peters | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 108,695 | 108,695 (0%) | 0% | 0 | Common Stock | |
| Jan G. J. van de Winkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 98,000 | 98,000 | - | - | Stock Option (Right to Buy) | |
| Julie O'Neill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 49,000 | 49,000 | - | - | Stock Option (Right to Buy) | |
| Terry Coelho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 49,000 | 49,000 | - | - | Stock Option (Right to Buy) | |
| David Ross Kaufman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 49,000 | 49,000 | - | - | Stock Option (Right to Buy) | |
| Malte Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 49,000 | 49,000 | - | - | Stock Option (Right to Buy) | |
| Timothy P. Reilly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 49,000 | 49,000 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 971,400 | 971,400 | - | - | Stock Option (Right to Buy) | |
| Reinhard Kandera | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 406,200 | 406,200 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 367,300 | 367,300 | - | - | Stock Option (Right to Buy) | |
| Roman Necina | Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 367,300 | 367,300 | - | - | Stock Option (Right to Buy) | |
| Mark Winderlich | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Mark Winderlich | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Reinhard Kandera | Director, Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.72 per share. | 21 Aug 2023 | 7,000 | 43,092 (0%) | 0% | 0.7 | 5,075 | Common Stock |
| Reinhard Kandera | Director, Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.71 per share. | 16 Aug 2023 | 8,000 | 36,092 (0%) | 0% | 0.7 | 5,712 | Common Stock |
| Joern Aldag | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.83 per share. | 07 Jul 2023 | 5,000 | 71,952 (0%) | 0% | 0.8 | 4,142 | Common Stock |
| Joern Aldag | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.81 per share. | 07 Jul 2023 | 5,000 | 66,952 (0%) | 0% | 0.8 | 4,050 | Common Stock |
| Joern Aldag | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.89 per share. | 05 Jul 2023 | 5,000 | 61,952 (0%) | 0% | 0.9 | 4,450 | Common Stock |
| Joern Aldag | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.89 per share. | 03 Jul 2023 | 5,000 | 56,952 (0%) | 0% | 0.9 | 4,456 | Common Stock |
| Reinhard Kandera | Director, Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.88 per share. | 30 Jun 2023 | 12,000 | 28,092 (0%) | 0% | 0.9 | 10,560 | Common Stock |
| Jan G. J. van de Winkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Julie O'Neill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Mary Theresa Coelho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| David Ross Kaufman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Malte Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Timothy P. Reilly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 513,600 | 513,600 | - | - | Stock Option (Right to Buy) | |
| Reinhard Kandera | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 214,800 | 214,800 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 194,200 | 194,200 | - | - | Stock Option (Right to Buy) | |
| Roman Necina | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 112,100 | 112,100 | - | - | Stock Option (Right to Buy) | |
| Christine D. Baker | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 275,800 | 275,800 | - | - | Stock Option (Right to Buy) | |
| Katia Schlienger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 184,000 | 184,000 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 275,250 | 275,250 | - | - | Stock Option (Right to Buy) | |
| Reinhard Kandera | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 92,950 | 92,950 | - | - | Stock Option (Right to Buy) | |
| Jan G. J. van de Winkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 92,950 | 92,950 | - | - | Stock Option (Right to Buy) | |
| David Ross Kaufman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Roman Necina | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 48,350 | 48,350 | - | - | Stock Option (Right to Buy) | |
| Christine D. Baker | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2022 | 275,250 | 275,250 | - | - | Stock Option (Right to Buy) | |
| Reinhard Kandera | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2022 | 92,950 | 92,950 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2022 | 92,950 | 92,950 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2022 | 48,350 | 48,350 | - | - | Stock Option (Right to Buy) | |
| Roman Necina | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2022 | 48,350 | 48,350 | - | - | Stock Option (Right to Buy) | |
| Christine D. Baker | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 39,853 | 39,853 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 01 Feb 2022 | 47,824 | 51,952 (0%) | 0% | 3 | 143,472 | Common Stock |
| Reinhard Kandera | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 01 Feb 2022 | 14,056 | 16,092 (0%) | 0% | 3 | 42,168 | Common Stock |
| Reinhard Kandera | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 23,427 | 23,427 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 24,888 | 24,888 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 01 Feb 2022 | 14,933 | 100,240 (0%) | 0% | 3 | 44,799 | Common Stock |
| Klaus Orlinger | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 01 Feb 2022 | 9,188 | 10,404 (0%) | 0% | 3 | 27,564 | Common Stock |
| Klaus Orlinger | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 12,654 | 12,654 | - | - | Stock Option (Right to Buy) | |
| Roman Necina | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 01 Feb 2022 | 12,892 | 14,876 (0%) | 0% | 3 | 38,676 | Common Stock |
| Roman Necina | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 21,486 | 21,486 | - | - | Stock Option (Right to Buy) | |
| Christine D. Baker | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 22,763 | 22,763 | - | - | Stock Option (Right to Buy) | |
| Christine D. Baker | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 01 Feb 2022 | 13,658 | 16,158 (0%) | 0% | 3 | 40,974 | Common Stock |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 207,600 | 207,600 | - | - | Stock Option (Right to Buy) | |
| Reinhard Kandera | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 69,300 | 69,300 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 95,250 | 95,250 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Sr. VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 26,050 | 26,050 | - | - | Stock Option (Right to Buy) | |
| Roman Necina | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 36,750 | 36,750 | - | - | Stock Option (Right to Buy) | |
| Christine D. Baker | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 49,950 | 49,950 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 16 Dec 2020 | 640 | 56,774 (0%) | 0% | 0.1 | 64 | Common Stock |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 5,965 | 7,669 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 11,367 | 14,208 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 31,656 | 8,079 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 640 | 39,735 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.76 per share. | 16 Dec 2020 | 16,478 | 77,403 (0%) | 0% | 11.8 | 193,781 | Common Stock |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 16 Dec 2020 | 29,628 | 93,881 (0%) | 0% | 0.1 | 2,963 | Common Stock |
| Igor Matushansky | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.70 per share. | 16 Dec 2020 | 11,501 | 64,253 (0%) | 0% | 11.7 | 134,562 | Common Stock |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 16 Dec 2020 | 19,360 | 75,754 (0%) | 0% | 0.1 | 1,936 | Common Stock |
| Igor Matushansky | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.70 per share. | 16 Dec 2020 | 380 | 56,394 (0%) | 0% | 11.7 | 4,446 | Common Stock |
| Jean-Charles Soria | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2020 | 19,200 | 19,200 | - | - | Stock Option (Right to Buy) | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2020 | 5,754 | 5,754 (0%) | 0% | 0 | Common Stock | |
| Sander van Deventer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2020 | 2,485 | 2,485 (0%) | 0% | 0 | Common Stock | |
| Graziano Seghezzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2020 | 4,708 | 4,708 (0%) | 0% | 0 | Common Stock | |
| Jan G. J. van de Winkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2020 | 9,153 | 9,153 (0%) | 0% | 0 | Common Stock | |
| Julie O'Neill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2020 | 4,969 | 4,969 (0%) | 0% | 0 | Common Stock | |
| Christoph Lengauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2020 | 4,603 | 4,603 (0%) | 0% | 0 | Common Stock | |
| David Ross Kaufman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2020 | 4,577 | 4,577 (0%) | 0% | 0 | Common Stock | |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 4,128 | 4,128 (0%) | 0% | 0 | Common Stock | |
| Reinhard Kandera | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 2,036 | 2,036 (0%) | 0% | 0 | Common Stock | |
| Igor Matushansky | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 2,736 | 56,134 (0%) | 0% | 0 | Common Stock | |
| Klaus Orlinger | EVP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 1,216 | 1,216 (0%) | 0% | 0 | Common Stock | |
| Roman Necina | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 1,984 | 1,984 (0%) | 0% | 0 | Common Stock | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| Sander van Deventer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| Graziano Seghezzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| Jan G. J. van de Winkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 19,200 | 19,200 | - | - | Stock Option (Right to Buy) | |
| Julie O'Neill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| Christoph Lengauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| David Ross Kaufman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2020 | 200,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Reinhard Kandera | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2020 | 77,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2020 | 65,200 | 0 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | EVP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2020 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Roman Necina | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2020 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.73 per share. | 29 Jan 2020 | 5,500 | 53,398 (0%) | 0% | 12.7 | 69,992 | Common Stock |
| Anders Lilja | Sr. VP, Technical Development | Sale of securities on an exchange or to another person at price $ 12.17 per share. | 23 Jan 2020 | 4,075 | 0 (0%) | 0% | 12.2 | 49,601 | Common Stock |
| Anders Lilja | Sr. VP, Technical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2020 | 7,568 | 13,098 | - | - | Stock Option (Right to Buy) | |
| Anders Lilja | Sr. VP, Technical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2020 | 4,075 | 0 | - | - | Stock Option (Right to Buy) | |
| Anders Lilja | Sr. VP, Technical Development | Sale of securities on an exchange or to another person at price $ 12.81 per share. | 23 Jan 2020 | 7,568 | 0 (0%) | 0% | 12.8 | 96,932 | Common Stock |
| Anders Lilja | Sr. VP, Technical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 23 Jan 2020 | 7,568 | 7,568 (0%) | 0% | 0.1 | 757 | Common Stock |
| Anders Lilja | Sr. VP, Technical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 23 Jan 2020 | 4,075 | 4,075 (0%) | 0% | 0.1 | 408 | Common Stock |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 16 Jan 2020 | 571 | 1,711 (0%) | 0% | 0.1 | 57 | Common Stock |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2020 | 6,789 | 7,741 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2020 | 571 | 14,530 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2020 | 1,140 | 0 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Sr. VP, Research | Sale of securities on an exchange or to another person at price $ 12.02 per share. | 16 Jan 2020 | 6,789 | 0 (0%) | 0% | 12.0 | 81,592 | Common Stock |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 16 Jan 2020 | 6,789 | 6,789 (0%) | 0% | 0.1 | 679 | Common Stock |
| Klaus Orlinger | Sr. VP, Research | Sale of securities on an exchange or to another person at price $ 11.56 per share. | 16 Jan 2020 | 1,711 | 0 (0%) | 0% | 11.6 | 19,781 | Common Stock |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 16 Jan 2020 | 1,140 | 1,140 (0%) | 0% | 0.1 | 114 | Common Stock |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 14 Jan 2020 | 1,142 | 8,500 (0%) | 0% | 0.1 | 114 | Common Stock |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2020 | 1,142 | 1,140 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2020 | 7,358 | 0 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Sr. VP, Research | Sale of securities on an exchange or to another person at price $ 11.30 per share. | 14 Jan 2020 | 8,500 | 0 (0%) | 0% | 11.3 | 96,053 | Common Stock |
| Klaus Orlinger | Sr. VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 14 Jan 2020 | 7,358 | 7,358 (0%) | 0% | 0.1 | 736 | Common Stock |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 19 Dec 2019 | 6,000 | 49,411 (0%) | 0% | 0.1 | 600 | Common Stock |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2019 | 19,891 | 25,575 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2019 | 6,000 | 40,375 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.93 per share. | 19 Dec 2019 | 10,404 | 58,898 (0%) | 0% | 9.9 | 103,312 | Common Stock |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 19 Dec 2019 | 19,891 | 69,302 (0%) | 0% | 0.1 | 1,989 | Common Stock |
| Sander van Deventer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| Graziano Seghezzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| Jan G. J. van de Winkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 28,800 | 28,800 | - | - | Stock Option (Right to Buy) | |
| Julie O'Neill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| Christoph Lengauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 9,600 | 9,600 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.10 per share. | 17 Dec 2019 | 26,312 | 54,895 (0%) | 0% | 0.1 | 2,631 | Common Stock |
| Igor Matushansky | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2019 | 26,312 | 46,375 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.87 per share. | 17 Dec 2019 | 11,484 | 43,411 (0%) | 0% | 7.9 | 90,379 | Common Stock |
| Roman Necina | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2019 | 125,008 | 125,008 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 604,656 | 604,656 | - | - | Stock Option (Right to Buy) | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 19,200 | 19,200 | - | - | Stock Option (Right to Buy) | |
| Reinhard Kandera | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 87,648 | 87,648 | - | - | Stock Option (Right to Buy) | |
| Sander van Deventer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 19,200 | 19,200 | - | - | Stock Option (Right to Buy) | |
| Graziano Seghezzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 19,200 | 19,200 | - | - | Stock Option (Right to Buy) | |
| Julie O'Neill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 6,924 | 6,924 | - | - | Stock Option (Right to Buy) | |
| Christoph Lengauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 6,924 | 6,924 | - | - | Stock Option (Right to Buy) | |
| Igor Matushansky | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 52,064 | 52,064 | - | - | Stock Option (Right to Buy) | |
| Anders Lilja | Sr. VP, Technical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 42,784 | 42,784 | - | - | Stock Option (Right to Buy) | |
| Klaus Orlinger | Sr. VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 42,784 | 42,784 | - | - | Stock Option (Right to Buy) | |
| David Ross Kaufman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 19,200 | 19,200 | - | - | Stock Option (Right to Buy) | |
| David Pinschewer | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2019 | 116,416 | 116,416 | - | - | Stock Option (Right to Buy) |